Dogwood Therapeutics Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
52.5%projected annual EPS growth
Analyst Coverage
3analysts covering
FY EPS (est.)
-$0.88next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Halneuron Phase 2b CINP Top-line Data Readout | 31 Oct 2026 |
Monitoring Framework
Key Performance Indicators
Halneuron Phase 2b CINP Trial Patient Enrollment Quarterly164.0Target: 210-240
Cash and Cash Equivalents (USD) Quarterly13.2MTarget: Sufficient to fund operations into Q4 2026
Watch Items
- Halneuron Phase 2b CINP Trial Top-line Data ReadoutTrigger: Fall 2026Action: Evaluate clinical efficacy (pain reduction vs placebo) and safety profile to determine progression to Phase 3.
- SP16 Phase 1b CIPN Trial InitiationTrigger: Mid-2026Action: Monitor enrollment and initial safety/tolerability data for the NCI-funded trial at the University of Virginia.
- Capital Runway and Financing NeedsTrigger: Q4 2026Action: Secure additional equity, debt, or partnership-based financing to extend operational runway beyond the fourth quarter of 2026.
Research as of 20 Jun 2026